Last reviewed · How we verify
Recombinant Activated Protein C
Recombinant Activated Protein C, marketed by Central Hospital, Nancy, France, holds a niche position in the therapeutic landscape. The drug's key strength lies in its unique mechanism of action, which differentiates it from other treatments in the market. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Recombinant Activated Protein C |
|---|---|
| Also known as | Xigris |
| Sponsor | Central Hospital, Nancy, France |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (PHASE1)
- A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis (PHASE3)
- Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PHASE2)
- Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma (PHASE1, PHASE2)
- Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC in Healthy Adult Volunteers (PHASE1)
- Activated Protein C and Corticosteroids for Human Septic Shock (PHASE3)
- To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Activated Protein C CI brief — competitive landscape report
- Recombinant Activated Protein C updates RSS · CI watch RSS
- Central Hospital, Nancy, France portfolio CI